These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

410 related articles for article (PubMed ID: 26703191)

  • 41. Programmed cell death in pathogenic fungi.
    Ramsdale M
    Biochim Biophys Acta; 2008 Jul; 1783(7):1369-80. PubMed ID: 18294459
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Candida biofilm resistance.
    Mukherjee PK; Chandra J
    Drug Resist Updat; 2004; 7(4-5):301-9. PubMed ID: 15533767
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Fungal Quorum-Sensing Molecules and Inhibitors with Potential Antifungal Activity: A Review.
    Mehmood A; Liu G; Wang X; Meng G; Wang C; Liu Y
    Molecules; 2019 May; 24(10):. PubMed ID: 31117232
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Nitrogen regulation of virulence in clinically prevalent fungal pathogens.
    Lee IR; Morrow CA; Fraser JA
    FEMS Microbiol Lett; 2013 Aug; 345(2):77-84. PubMed ID: 23701678
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Strategies to manage antifungal drug resistance.
    Tseng HK; Perfect JR
    Expert Opin Pharmacother; 2011 Feb; 12(2):241-56. PubMed ID: 21226635
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The potential of respiration inhibition as a new approach to combat human fungal pathogens.
    Duvenage L; Munro CA; Gourlay CW
    Curr Genet; 2019 Dec; 65(6):1347-1353. PubMed ID: 31172256
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A case of endocarditis caused by the yeast Pichia fabianii with biofilm production and developed in vitro resistance to azoles in the course of antifungal treatment.
    Hamal P; Ostransky J; Dendis M; Horváth R; Ruzicka F; Buchta V; Vejsova M; Sauer P; Hejnar P; Raclavsky V
    Med Mycol; 2008 Sep; 46(6):601-5. PubMed ID: 18608935
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Biofilm lifestyle of Candida: a mini review.
    Seneviratne CJ; Jin L; Samaranayake LP
    Oral Dis; 2008 Oct; 14(7):582-90. PubMed ID: 19076549
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Invertebrate models of fungal infection.
    Arvanitis M; Glavis-Bloom J; Mylonakis E
    Biochim Biophys Acta; 2013 Sep; 1832(9):1378-83. PubMed ID: 23517918
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Biofilm caused by fungi--structure, quorum sensing, morphogenetic changes, resistance to drugs].
    Nowak M; Kurnatowski P
    Wiad Parazytol; 2009; 55(1):19-25. PubMed ID: 19579780
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Opportunistic yeast pathogens: reservoirs, virulence mechanisms, and therapeutic strategies.
    Polvi EJ; Li X; O'Meara TR; Leach MD; Cowen LE
    Cell Mol Life Sci; 2015 Jun; 72(12):2261-87. PubMed ID: 25700837
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Exploiting amoeboid and non-vertebrate animal model systems to study the virulence of human pathogenic fungi.
    Mylonakis E; Casadevall A; Ausubel FM
    PLoS Pathog; 2007 Jul; 3(7):e101. PubMed ID: 17676994
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The role of neutral glycolipids and phospholipids in myxovirus-induced membrane fusion.
    Huang RT
    Lipids; 1983 Jul; 18(7):489-92. PubMed ID: 6312239
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Siderophores; iron scavengers: the novel & promising targets for pathogen specific antifungal therapy.
    Balhara M; Chaudhary R; Ruhil S; Singh B; Dahiya N; Parmar VS; Jaiwal PK; Chhillar AK
    Expert Opin Ther Targets; 2016 Dec; 20(12):1477-1489. PubMed ID: 27797604
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Natural Sources as Innovative Solutions Against Fungal Biofilms.
    Girardot M; Imbert C
    Adv Exp Med Biol; 2016; 931():105-25. PubMed ID: 27115410
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Antifungal peptides: To be or not to be membrane active.
    Rautenbach M; Troskie AM; Vosloo JA
    Biochimie; 2016 Nov; 130():132-145. PubMed ID: 27234616
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Dimorphism and virulence in fungi.
    Klein BS; Tebbets B
    Curr Opin Microbiol; 2007 Aug; 10(4):314-9. PubMed ID: 17719267
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Fungal G-protein-coupled receptors: mediators of pathogenesis and targets for disease control.
    Brown NA; Schrevens S; van Dijck P; Goldman GH
    Nat Microbiol; 2018 Apr; 3(4):402-414. PubMed ID: 29588541
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Emerging moulds: epidemiological trends and antifungal resistance.
    Miceli MH; Lee SA
    Mycoses; 2011 Nov; 54(6):e666-78. PubMed ID: 21672045
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Aspects of fungal pathogenesis in humans.
    van Burik JA; Magee PT
    Annu Rev Microbiol; 2001; 55():743-72. PubMed ID: 11544373
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.